Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.36 |
| ▸ | IP6K1 | Q92551 | 6/20 | 0.35 |
| ▸ | IP6K3 | Q96PC2 | 3/20 | 0.34 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | QPCT | Q16769 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3276925 | 0.80 | LRRK2 (0.41) | PARP1IP6K1IP6K3 | |
| SCHEMBL3275911 | 0.73 | L3MBTL1 (0.35) | PARP1IP6K1IP6K3IP6K2PTPN1 | |
| SCHEMBL6584812 | 0.68 | PDE4B (0.36) | PARP1ALDH1A1HSD17B10 | |
| SCHEMBL9918614 | 0.66 | PTPN1 (0.35) | PTPN1 | |
| SCHEMBL22749363 | 0.66 | PIM1 (0.43) | PARP1IP6K1IP6K3IP6K2ALDH1A1 | |
| SCHEMBL21808090 | 0.64 | PARP1 (0.56) | PARP1IP6K1IP6K3 | |
| SCHEMBL3276246 | 0.64 | LRRK2 (0.40) | PARP1KMT2A | |
| SCHEMBL3276941 | 0.64 | LRRK2 (0.37) | PARP1ALDH1A1HPGDHSD17B10 | |
| SCHEMBL6624213 | 0.63 | PTPN1 (0.33) | ALDH1A1MEN1KMT2APTPN1 | |
| SCHEMBL16705975 | 0.63 | PDE4B (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038050-A1 | Quinazoline derivatives for the treatment of t cell mediated diseases | ASTRAZENECA AB (SE) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038050-A1 | Quinazoline derivatives for the treatment of t cell mediated diseases | CD4, HLA-DRB1, IFNG | PARP1 1643/4885IP6K1 4283/4885IP6K3 3820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.